Free Helpline
We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Explore the phases of Acute Myeloid Leukemia (AML) chemotherapy, including induction, consolidation, and maintenance. Understand the drugs, side effects, prognosis, and when to seek medical help.
Acute Myeloid Leukemia, or AML, is a rapid and aggressive form of blood cancer. It affects the myeloid cells, which are responsible for creating red blood cells, white blood cells, and platelets. In AML, these cells don't mature properly and instead accumulate in the bone marrow and blood, crowding out healthy cells. Because it's a fast-growing cancer, starting treatment quickly is paramount. Chemotherapy is typically the first line of attack, employing powerful drugs to eradicate the cancer cells. This is not a simple treatment; it's an intense journey often divided into distinct phases designed to achieve remission and prevent recurrence. This guide will walk you through these phases, the drugs commonly used, and what to expect during this challenging time.
Chemotherapy for AML isn't a one-size-fits-all approach. It's structured into several phases, each with a specific objective.
This initial phase is short but incredibly potent. Its primary goals are to swiftly eliminate leukemia cells from your bloodstream and reduce the number of immature cells, known as blasts, in your bone marrow to a normal level. Induction therapy is usually administered in a hospital setting, and you might need to stay for several weeks. During this intensive period, the chemotherapy drugs will target not only the cancer cells but also your healthy bone marrow cells. This means your blood counts, including white blood cells, red blood cells, and platelets, will likely drop significantly. To manage this, you might receive supportive treatments like medications to boost your white blood cell count, blood transfusions, or platelet transfusions. A low white blood cell count dramatically increases your risk of infection, so vigilant hygiene practices, like frequent handwashing for both you and visitors, are essential. Avoiding potential sources of infection, such as fresh flowers and plants (which can harbor mold), is also advised.
The drugs most commonly used for induction chemotherapy include:
This combination is frequently referred to as the '7 + 3' regimen. For individuals with specific heart conditions, anthracyclines might not be suitable. In such cases, alternative drugs like fludarabine (Fludara) or etoposide may be considered. Corticosteroids, such as prednisone or dexamethasone, are also frequently part of the induction regimen.
After the induction phase, a bone marrow biopsy is performed to assess the response. If remission isn't achieved, induction therapy might be repeated, or a stem cell transplant could be recommended.
Once you have recovered from the intense induction phase, consolidation therapy begins. This phase is absolutely critical. Without it, the leukemia is highly likely to return. The main objective here is to seek and destroy any remaining leukemia cells that might have evaded detection during induction. Treatment is delivered in cycles, with planned breaks for rest and recovery between each cycle. Consolidation therapy can span several months, typically ranging from 3 to 6 months.
A common approach during consolidation involves high-dose cytarabine (HiDAC). This is usually given over 5 days and repeated every 4 weeks. This intensive treatment aims to achieve a lasting remission.
This phase is most commonly employed for a specific subtype of AML known as acute promyelocytic leukemia (APL). It involves a less intensive, lower-dose chemotherapy regimen that might continue for months, or even years. The goal is to maintain the remission achieved and further reduce the risk of relapse.
Chemotherapy is a powerful tool, but it comes with side effects. These can vary significantly depending on the specific drugs used, the dosage, and the duration of treatment. It's essential to have an open conversation with your oncology team about potential side effects and how to manage them.
Your dedicated oncology team will monitor you closely throughout treatment, managing side effects and adjusting the treatment plan as needed. Open communication is your strongest ally.
The outlook for AML patients has improved significantly over the years, thanks to advancements in treatment. According to the American Cancer Society, approximately two-thirds of individuals achieve remission after standard induction chemotherapy. For those with the APL subtype, the remission rate is even higher, with about 9 out of 10 achieving remission. With consolidation and maintenance therapies, about 80-90% of APL patients experience long-term remission.
Survival rates are an important metric, but it's vital to understand they are based on data from patients diagnosed and treated several years ago. They do not yet fully reflect the impact of the latest therapies. Generally, people younger than 60 tend to have a better prognosis than older individuals. The overall 5-year relative survival rate for AML stands at around 29.5 percent. For children diagnosed with AML, the survival rate is considerably higher, ranging from 65% to 70%.
It's encouraging to note that since 2017, the U.S. Food and Drug Administration (FDA) has approved ten new therapies specifically for AML, offering renewed hope and improved outcomes for many patients.
AML is a serious condition that requires immediate medical attention. If you experience any of the following symptoms, it is imperative to see a doctor or go to the nearest emergency room without delay:
Early diagnosis and prompt treatment are key factors in achieving the best possible outcomes for AML.
While AML is a challenging disease, remission is achievable for many patients, and long-term survival is increasingly common, especially with newer treatments. For some, particularly with subtypes like APL, a cure is possible. The goal of treatment is to achieve and maintain remission.
Induction therapy is the initial, intense phase aimed at rapidly reducing leukemia cells. Consolidation therapy follows, designed to eliminate any remaining hidden cancer cells to prevent the leukemia from returning.
This depends heavily on the phase of treatment, the intensity of the therapy, and how your body responds. During induction, it's unlikely due to the intensity and potential side effects. In later, less intensive phases like maintenance, some individuals might be able to return to work on a part-time or modified basis, but this must be discussed thoroughly with your medical team.
Long-term effects can vary but may include an increased risk of secondary cancers, heart problems, lung issues, infertility, and cognitive changes ('chemo brain'). Regular follow-up care is essential to monitor for and manage these potential long-term effects.
Learn about potential side effects of CML treatments like TKIs, interferon, chemotherapy, and stem cell transplants. Understand what to expect and how to communicate with your doctor for effective management.
April 1, 2026
Discover essential support resources, financial aid options, and community connections for individuals navigating life with Chronic Myeloid Leukemia (CML). Find practical advice and empathetic guidance.
April 1, 2026
Explore targeted therapy for multiple myeloma. Learn how these precision treatments work, their types, potential side effects, and how they're used alongside other therapies to manage this blood cancer.
April 1, 2026